Gensight Biologics SA, of Paris, reported additional data after 78 weeks of follow-up in its phase I/II trial, confirming the safety and tolerability profile of GS010, while demonstrating sustainable visual acuity improvement in patients with Leber's hereditary optic neuropathy (LHON). Read More
Pvp Biologics Inc., of Seattle, a University of Washington (UW) spinout, said it is advancing an enzyme, Kumamax, designed to target parts of gluten that cause the autoimmune reaction leading to celiac disease. Read More
Celsion Corp., of Lawrenceville, N.J., said it entered a definitive agreement with several institutional investors to purchase an aggregate of about $1.8 million of shares of common stock in a registered direct offering. Read More
SHANGHAI – Shanghai-based Generon Corp. Ltd. was acquired by the world's leading manufacturer of vitamin B5 API, Yifan Pharmaceutical Co. Ltd., a public company listed in Shenzhen. Yifan has a portfolio of drugs approved in China for gynecology, pediatrics and dermatology, a portion of which are traditional Chinese medicine (TCM) products. Read More
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer. Read More
LONDON – Psioxus Therapeutics Ltd. has signed a potential $936 million deal with Bristol-Myers Squibb Co. (BMS) for NG-348, an armed oncolytic virus that delivers the genes for two T-cell mobilizing proteins. Read More
Novartis AG's farnesoid X receptor (FXR) agonists represent "an excellent first opportunity for combination products" in liver disease, Conatus Pharmaceuticals Inc. CEO Steven Mento told BioWorld Today, but not necessarily the only prospect for pairing with oral pan-caspase inhibitor emricasan. "There could be others." Read More
While most analysts and investors were focused on its discussions with potential European partners, Akebia Therapeutics Inc. turned to Asia, again, for a U.S. development and commercialization collaborator for its lead candidate, vadadustat. Read More
